Advancing the antituberculosis activity of nitropicolinic acids and amides

Ambitious milestones set by the World Health Organisation (WHO) to end the tuberculosis epidemic by 2030 currently appear out of reach, and there remains an urgent need to develop more effective novel therapies. While exploring dipicolinic acid derivatives as putative glutamate racemase inhibitors, we recently discovered 6-nitropicolinamides as promising antituberculosis agents. SAR studies on the non-cytotoxic N-[4-(trifluoromethoxy)benzyl] hit 20 (MIC<sub>90</sub> 1.4 μM) confirmed the importance of the 6-nitro group and amide NH; side chain extension enhanced potency but reduced aqueous solubility, and some analogues were rapidly metabolised. The best new candidate (77: MIC<sub>90</sub> 0.30 μM) was well tolerated in mice and provided an adequate pharmacokinetic profile, although a time-kill assay indicated largely bacteriostatic activity. An analysis of its effects on cell wall lipids and mycolic acids revealed changes consistent with inhibiting arabinogalactan biosynthesis, and further testing against mutant or overexpressing mycobacterial strains identified the enzyme target as decaprenylphosphoryl-β-d-ribose 2'-oxidase (DprE1).

Authors

Institutions

Publication Details

Journal
European Journal of Medicinal Chemistry
Published
2025-10-30
DOI
https://doi.org/10.1016/j.ejmech.2025.118324
Primary Topic
Tuberculosis Research and Epidemiology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Advancing the antituberculosis activity of nitropicolinic acids and amides

Sher Bahadar Khan, Dejan Nikolić, Kurt L. Krause, Giovanni Stelitano et al.
European Journal of Medicinal Chemistry
Tuberculosis Research and Epidemiology
article

Advancing the antituberculosis activity of nitropicolinic acids and amides

Sher Bahadar Khan, Dejan Nikolić, Kurt L. Krause, Giovanni Stelitano, William A. Denny, Chen‐Yi Cheung, Maria Rosalia Pasca, Deborah Recchia, Gregory Murray Cook, Jana Korduláková, Scott G. Franzblau, Andrew M. Thompson, A.C. Campbell, Monika Záhorszká, Gauri Shetye, Matthew B. McNeil, Baojie Wan
article en

Abstract

Ambitious milestones set by the World Health Organisation (WHO) to end the tuberculosis epidemic by 2030 currently appear out of reach, and there remains an urgent need to develop more effective novel therapies. While exploring dipicolinic acid derivatives as putative glutamate racemase inhibitors, we recently discovered 6-nitropicolinamides as promising antituberculosis agents. SAR studies on the non-cytotoxic N-[4-(trifluoromethoxy)benzyl] hit 20 (MIC<sub>90</sub> 1.4 μM) confirmed the importance of the 6-nitro group and amide NH; side chain extension enhanced potency but reduced aqueous solubility, and some analogues were rapidly metabolised. The best new candidate (77: MIC<sub>90</sub> 0.30 μM) was well tolerated in mice and provided an adequate pharmacokinetic profile, although a time-kill assay indicated largely bacteriostatic activity. An analysis of its effects on cell wall lipids and mycolic acids revealed changes consistent with inhibiting arabinogalactan biosynthesis, and further testing against mutant or overexpressing mycobacterial strains identified the enzyme target as decaprenylphosphoryl-β-d-ribose 2'-oxidase (DprE1).

European Journal of Medicinal ChemistryVol. 302(Pt 2)
University of Pavia (IT), University of Illinois Chicago (US), Maurice Wilkins Centre (NZ), Comenius University Bratislava (SK), University of Otago (NZ)
Openalex Percentile: Top 63%
Tuberculosis Research and Epidemiology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.